Flow cytometric analysis of Mouse CD184 expression on C57BL/6 mouse thymocytes. C57BL/6 mouse thymocytes were stained with Alexa Fluor® 647 Rat Anti-Mouse CD4 Antibody and either FITC Rat IgG2b, κ Isotype Control (Left panel) or SDT FITC Rat Anti-Mouse CD184 Antibody (Right panel) at 5μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
FITC Rat Anti-Mouse CD184 Antibody (S-R670)
FITC Rat Anti-Mouse CD184 Antibody (S-R670)
Price:
Regular price
$100 USD
Regular price
Sale price
$100 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | CD184 |
| Synonyms | C-X-C chemokine receptor type 4; CXC-R4; CXCR-4; Fusin; Leukocyte-derived seven transmembrane domain receptor (LESTR); Pre-B-cell-derived chemokine receptor (PB-CKR); Stromal cell-derived factor 1 receptor (SDF-1 receptor); Cmkar4; Lestr; Sdf1r; Cxcr4 |
| Location | Lysosome, Endosome, Cell membrane, Cell junction |
| Accession | P70658 |
| Clone Number | S-R670 |
| Antibody Type | Rat mAb |
| Isotype | IgG2b,k |
| Application | FCM |
| Reactivity | Ms |
| Positive Sample | BALB/c mouse thymocytes |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | FITC |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Ms |
Background
CD184, also known as CXCR4, is a seven-transmembrane G-protein-coupled chemokine receptor that—after binding its unique ligand CXCL12 (SDF-1)—triggers multiple signaling cascades (PI3K/AKT, JAK/STAT, ERK1/2, Hedgehog) governing immune cell trafficking, plasma-cell homing to bone-marrow niches, embryonic development, hematopoiesis, angiogenesis, and cancer stem-cell maintenance, while its overexpression or mutations underlie WHIM syndrome, HIV entry, tumor progression and metastasis, making it a key therapeutic target in oncology and immunology.
Picture
Picture
FC
